期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 5, 页码 2659-2668出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c01779
关键词
-
资金
- Aventis Foundation (Life Science Bridge Award)
- LOEWE center Translational Medicine and Pharmacology (TMP)
The study identified fragment-sized Nurr1 agonists that can activate Nurr1 in various cellular environments and enhance gene expression in human astrocytes. These findings provide important insights into Nurr1 regulation.
The ligand-activated transcription factor nuclear receptor related-1 (Nurr1) exhibits great potential for neuro-degenerative disease treatment, but potent Nurr1 modulators to further probe and validate the nuclear receptor as a therapeutic target are lacking. We have systematically studied the structure-activity relationship of the 4-amino-7-chloroquinoline scaffold contained in Nurr1 activators amodiaquine and chloroquine and discovered fragment-like analogues that activated Nurr1 in several cellular settings. The most active descendants promoted the transcriptional activity of Nurr1 on human response elements as monomer, homodimer, and heterodimer and markedly enhanced Nurr1-dependent gene expression in human astrocytes. As a tool to elucidate mechanisms involving in Nurr1 activation, these Nurr1 agonists induced robust recruitment of NCoR1 and NCoR2 co-regulators to the Nurr1 ligand binding domain and promoted Nurr1 dimerization. These findings provide important insights in Nurr1 regulation. The fragment-sized Nurr1 agonists are appealing starting points for medicinal chemistry and valuable early Nurr1 agonist tools for pharmacology and chemical biology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据